Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

DLD/TO Assemblies of JRS

Research output: Contribution to journalReview article

Abstract

Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.

Original languageEnglish
JournalRespiratory Investigation
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Interstitial Lung Diseases
Lung Neoplasms
Therapeutics
Clinical Trials
Lung Injury
Immunotherapy
Lung Diseases
Thorax
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. / DLD/TO Assemblies of JRS.

In: Respiratory Investigation, 01.01.2019.

Research output: Contribution to journalReview article

@article{495dc1f16a324dd3997a91f7b7f693d3,
title = "Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia",
abstract = "Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.",
author = "{DLD/TO Assemblies of JRS} and Takashi Ogura and N. Takigawa and Keisuke Tomii and Kazuma Kishi and Yoshikazu Inoue and Eiki Ichihara and S. Homma and Kazuhisa Takahashi and Hiroaki Akamatsu and Satoshi Ikeda and Naohiko Inase and Tae Iwasawa and Yuichiro Ohe and Hiromitsu Ohta and Hiroshi Onishi and I. Okamoto and Kazumasa Ogawa and K. Kasahara and Hiroki Karata and Takumi Kishimoto and Yuka Kitamura and Akihiko Gemma and Hirotsugu Kenmotsu and Hiroyuki Sakashita and Susumu Sakamoto and Katsutoshi Sekine and Yuichi Takiguchi and Yuji Tada and Shinichi Toyooka and Yuko Nakayama and Yasuhiko Nishioka and Koichi Hagiwara and Masaki Hanibuchi and J. Fukuoka and Yuji Minegishi and Toyoshi Yanagihara and Nobuyuki Yamamoto and Hiromasa Yamamoto and Mina Gaga and Fong, {Kwun M.} and Powell, {Charles A.} and Katsuyuki Kiura",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.resinv.2019.06.001",
language = "English",
journal = "Respiratory Investigation",
issn = "2212-5345",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia

AU - DLD/TO Assemblies of JRS

AU - Ogura, Takashi

AU - Takigawa, N.

AU - Tomii, Keisuke

AU - Kishi, Kazuma

AU - Inoue, Yoshikazu

AU - Ichihara, Eiki

AU - Homma, S.

AU - Takahashi, Kazuhisa

AU - Akamatsu, Hiroaki

AU - Ikeda, Satoshi

AU - Inase, Naohiko

AU - Iwasawa, Tae

AU - Ohe, Yuichiro

AU - Ohta, Hiromitsu

AU - Onishi, Hiroshi

AU - Okamoto, I.

AU - Ogawa, Kazumasa

AU - Kasahara, K.

AU - Karata, Hiroki

AU - Kishimoto, Takumi

AU - Kitamura, Yuka

AU - Gemma, Akihiko

AU - Kenmotsu, Hirotsugu

AU - Sakashita, Hiroyuki

AU - Sakamoto, Susumu

AU - Sekine, Katsutoshi

AU - Takiguchi, Yuichi

AU - Tada, Yuji

AU - Toyooka, Shinichi

AU - Nakayama, Yuko

AU - Nishioka, Yasuhiko

AU - Hagiwara, Koichi

AU - Hanibuchi, Masaki

AU - Fukuoka, J.

AU - Minegishi, Yuji

AU - Yanagihara, Toyoshi

AU - Yamamoto, Nobuyuki

AU - Yamamoto, Hiromasa

AU - Gaga, Mina

AU - Fong, Kwun M.

AU - Powell, Charles A.

AU - Kiura, Katsuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.

AB - Dramatic progress in targeted therapy and immunotherapy has been changing clinical practices in lung cancer. With the accumulation of clinical practice, it has become clear that pre-existing interstitial pneumonia (IP) could be a risk factor for drug-induced lung injury, which has enhanced awareness regarding the difficulty in treating lung cancer with comorbid IP. Unfortunately, there is only low-grade evidence in the field of lung cancer with comorbid IP, because almost all clinical trials exclude such patients. There have been very few specialized clinical trials for patients with lung cancer and underlying IPs thus far. Therefore, it is necessary to treat such cases empirically or to give up on the treatment itself. Considering these circumstances, establishing how to treat lung cancer with comorbid IP is an urgent issue. This paper is a summary of the official statement reported by the Diffuse Lung Disease/Thoracic Oncology Assembly and the Japanese Respiratory Society (JRS) in 2017, which attempts to approach lung cancer with comorbid IP systematically.

UR - http://www.scopus.com/inward/record.url?scp=85069959540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069959540&partnerID=8YFLogxK

U2 - 10.1016/j.resinv.2019.06.001

DO - 10.1016/j.resinv.2019.06.001

M3 - Review article

AN - SCOPUS:85069959540

JO - Respiratory Investigation

JF - Respiratory Investigation

SN - 2212-5345

ER -